Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SL
Silexion Therapeutics Corp Warrant
SLXNW
Volume
48.07K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SL
SLXNW
SL
Silexion Therapeutics Corp Warrant
SLXNW
News
·
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Mkt Cap
N/A
Volume
48.06K
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics announced the first patient has been successfully dosed in its Phase 2/3 clinical trial of SIL204, an RNAi therapy for locally advanced pancreatic cancer with KRAS mutations. The trial combines direct intratumoral EUS-guided delivery with subcutaneous dosing alongside standard chemotherapy. The study includes an initial safety cohort of ~18 patients followed by expansion to ~166 patients across Israel and Germany.
GlobeNewswire Inc. · Sep 30, 2026
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion Therapeutics has initiated GMP clinical manufacturing of SIL204, its next-generation siRNA therapy targeting mutated KRAS in pancreatic cancer, in collaboration with CDMO Catalent at its Limoges, France facility. The company received approval from Tel Aviv Sourasky Medical Center's Helsinki Ethics Committee for its planned Phase 2/3 trial in locally advanced pancreatic cancer, following earlier approvals from the Israeli Ministry of Health and a clinical trial application submission to Germany's BfArM.
GlobeNewswire Inc. · May 13, 2026
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
Silexion Therapeutics received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices regarding its planned Phase 2/3 clinical trial for SIL204, a potential treatment for locally advanced pancreatic cancer. The guidance provides regulatory clarity and supports the company's planned trial initiation in Q2 2026.
GlobeNewswire Inc. · Dec 2, 2025
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Silexion Therapeutics reported strong preclinical results for SIL204, a potential cancer therapy targeting KRAS mutations, raised $9.5 million in financing, and remains on track to initiate Phase 2/3 clinical trials in the first half of 2026.
GlobeNewswire Inc. · Nov 12, 2025
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
Silexion Therapeutics demonstrated successful systemic distribution of SIL204 to major pancreatic cancer metastatic sites in preclinical studies, showing tumor burden reductions across liver, peritoneum, and lung, with plans to initiate Phase 2/3 trials in H1 2026.
GlobeNewswire Inc. · Sep 11, 2025
Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Silexion Therapeutics reported strong preclinical data for SIL204 across multiple KRAS-driven cancer types, demonstrating up to 97% cancer cell inhibition. The company is preparing to initiate Phase 2/3 clinical trials in 2026 and maintains its Nasdaq listing after a reverse stock split.
GlobeNewswire Inc. · Aug 12, 2025
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Silexion Therapeutics, a clinical-stage biotech company, announced the exercise of outstanding warrants for $3.3 million in gross proceeds. The company plans to use the funds for general corporate purposes.
GlobeNewswire Inc. · Jan 29, 2025
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings
U.S. stock futures were mixed ahead of the Federal Reserve's interest rate decision and key earnings reports from major tech companies. Investors are cautious as they await the Fed's policy announcement and guidance.
Benzinga · Jan 29, 2025
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
Silexion Therapeutics, a clinical-stage biotech company, announced a 1-for-9 reverse share split to maintain its Nasdaq listing and support its strategic growth initiatives. The reverse split is expected to help the company comply with Nasdaq requirements and enhance its market position.
GlobeNewswire Inc. · Nov 22, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
SL
SLXNW
Silexion Therapeutics Corp Warrant
Buy
Sell
Market
Limit
Soon
SLXNW
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any SLXNW yet.
Related Tickers
Earnings